These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2524317)

  • 1. [A pharmacological and clinical review on the activity of a bovine factor VIII derivative obtained by enzymatic hydrolysis].
    Ammannati P; Siravo D; Conte B
    Clin Ter; 1989 Feb; 128(4):271-90. PubMed ID: 2524317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease of bleeding time by a peptide fraction from bovine factor VIII in laboratory animals.
    Gervasi GB; Bartoli C; Carpita G; Baldacci M
    Arzneimittelforschung; 1988 Sep; 38(9):1268-70. PubMed ID: 3146984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a form of bovine factor VIII which does not aggregate human platelets.
    Kirby EP
    Thromb Haemost; 1981 Aug; 46(2):479-84. PubMed ID: 6795738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    Weiss HJ; Rogers J; Brand H
    J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic analysis of bovine factor VIII in the hemophilic dog.
    Gentry PA; Kirby EP; Gentry RD
    Thromb Haemost; 1981 Aug; 46(2):485-8. PubMed ID: 6795739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.
    Bennett B; Ratnoff OD
    J Clin Invest; 1972 Oct; 51(10):2593-6. PubMed ID: 4626847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A chromone with angioprotecting action in local ocular therapy].
    Rouher F; Plaussu P
    Bull Soc Ophtalmol Fr; 1971 Apr; 71(4):411-5. PubMed ID: 4948148
    [No Abstract]   [Full Text] [Related]  

  • 9. Dissociation between human platelet agglomerating activity and factor VIII procoagulant activity of bovine plasma preparations by chemical treatment. II. Effect of periodate oxidation.
    Mello Périssé AC; Soria J; Soria C; Mester L
    Pathol Biol (Paris); 1973 Nov; 21():Suppl:63-5. PubMed ID: 4357696
    [No Abstract]   [Full Text] [Related]  

  • 10. Decrease of diffusion of glycosylated albumin in retinal microcirculation by peptide fraction from bovine factor VIII.
    Ammannati P; Siravo D; Azzarelli L; Chimenti M; Salvetti O; Farina C; Gervasi GB
    Arzneimittelforschung; 1989 Jun; 39(6):661-4. PubMed ID: 2505782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recombinant factor VIIa (eptacog alfa): a new therapeutic option for patients with severe bleeding disorder due to inhibitory antibodies against a coagulation factor].
    Turkstra F; Levi M; Koopman MM; Wester JP; Stoutenbeek CP; Briët E
    Ned Tijdschr Geneeskd; 1998 Jun; 142(25):1464-7. PubMed ID: 9752060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.
    O'Brien DP; Giles AR; Tate KM; Vehar GA
    J Clin Invest; 1988 Jul; 82(1):206-11. PubMed ID: 3134399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of neutrophils in breakdown of the blood-retinal barrier following intravitreal injection of platelet-activating factor.
    Smith D; Lee EK; Saloupis P; Davis JK; Hatchell DL
    Exp Eye Res; 1994 Oct; 59(4):425-32. PubMed ID: 7859817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of bactericidal/permeability-increasing protein (BPI) analogues on retinal neovascularization and retinal pericyte growth.
    Rauniyar RK; Suzuma K; King AL; Aiello LP; King GL
    Invest Ophthalmol Vis Sci; 2002 Feb; 43(2):503-9. PubMed ID: 11818397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic use of a peptide fraction derived from bovine factor VIII in epistaxis in children].
    Tarantino V; Stura M; Cingolani M
    Minerva Pediatr; 1989 Nov; 41(11):549-51. PubMed ID: 2533661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Procoagulant properties of beta/gamma-thrombin].
    Semenova OA; Strukova SM
    Vopr Med Khim; 1982; 28(4):137-40. PubMed ID: 6810543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
    Liu T; Scallan CD; Broze GJ; Patarroyo-White S; Pierce GF; Johnson KW
    Thromb Haemost; 2006 Jan; 95(1):68-76. PubMed ID: 16543964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig.
    Dickneite G; Nicolay U; Friesen HJ; Reers M
    Thromb Haemost; 1998 Jul; 80(1):192-8. PubMed ID: 9684809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The different action of bovine and human factor VIII (anti-haemophilic globulin) on factor X consumption during coagulation].
    Mayer G; Mayer S; Waitz R
    Rev Fr Etud Clin Biol; 1969 Dec; 14(10):1028-31. PubMed ID: 5377890
    [No Abstract]   [Full Text] [Related]  

  • 20. Polypeptide fraction from bovine factor VIII used in fluorangiography.
    Ammannati P; Siravo D; Gervasi GB; Gelso E; Baldacci M
    Ophthalmologica; 1988; 197(1):51-5. PubMed ID: 3141864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.